Advanced Melanoma, Advanced Solid Tumor
Conditions
Brief summary
The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive). Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.
Interventions
DRUGBT02
monoclonal antibody injection with intravenous administration every 2 or 3 weeks
Sponsors
Peking University Cancer Hospital and Institute
Biotroy Therapeutics
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic malignant melanoma (except for uveal melanoma) who have failed in the prior systemic therapy . 2. Adequate organ and hematologic function. 3. At least 1 extracranial measurable lesion. 4. An ECOG activity status score of 0-1. 5. A life expectancy of ≥ 3 months. 6. Eligible participants of childbearing potential (both males and females) must agree to using effective contraception throughout the study period. 7. Good compliance and willingness to follow up.
Exclusion criteria
1. Prior to first dose, received systemic antitumor therapy , scheduled major surgical procedure within 4 weeks , received systemic immunostimulants within 5 half-lives and systemic corticosteroids or other immunosuppressive medications within 14 days. 2. A history of active autoimmune disease within the past 2 years. 3. A history of clinically significant cardiovascular disease, severe cardiac rhythm/conduction abnormalities or LVEF\<50%. A history of severe pulmonary disease that may lead to severe episodes of dyspnea. 4. A severe acute or chronic infection when enrollment. 5. Remaining the toxic reaction in previous anti-tumor therapy that has not recovered to ≤ Grade 1 . 6. Unresolved \> grade 1 irAE or the history of a grade ≥ 3 irAE in previous immunotherapy, or known hypersensitivity to the formulation of the investigational product. 7. Clinically active CNS metastases or meningeal metastases. 8. A history of other type of malignancies. 9. Received a live attenuated vaccine within 28 days prior to the administration of the investigational product. 10. Poor compliance. 11. A history of alcohol/drugs abuse. 12. Current pregnancy or breastfeeding. 13. Other severe physical or mental illnesses or abnormal laboratory test results that the investigator deems unsuitable for participation in this study considering safety and compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events | Through the study completion, an average of 2 years |
| Dose limited toxicity(DLT) | Through the dose escalation phase, an average of 8 months |
| Maximum tolerable dose(MTD) | Through the dose escalation phase, an average of 8 months |
| Recommended phase 2 dose(RP2D) | Through the study completion, an average of 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate (DCR) on tumor assessments | Through the study completion, an average of 2 years |
| Mean and median Area under the curve (AUC) of BT02 following first dose and repeated administration at each dose level | Through the study completion, an average of 2 years |
| Objective response rate (ORR) on tumor assessments | Through the study completion, an average of 2 years |
| ADA and NAb incidence | Through the study completion, an average of 2 years |
| Mean and median Maximum concentration (Cmax) of BT02 following first dose and repeated administration at each dose level | Through the study completion, an average of 2 years |
| Progression-free survival (PFS) on tumor assessments | Through the study completion, an average of 2 years |
| Overall survival (OS) | Through the study completion, an average of 2 years |
| Duration of response (DoR) on tumor assessments | Through the study completion, an average of 2 years |
Contacts
Primary ContactClinical development director
Outcome results
None listed